Azithromycin and doxycycline not beneficial in managing covid

Results from the RECOVERY trial and the PRINCIPLE trial have shown no significant clinical benefit of

· oral or intravenous azithromycin in patients hospitalised with COVID-19

· oral azithromycin in patients with early stages of COVID-19 managed at home

Results from the PRINCIPLE trial have additionally shown there is no significant clinical benefit of oral doxycycline in patients with early stages of COVID-19 managed at home.

Within primary care it is recommended azithromycin or doxycycline should NOT be used in the primary management of COVID-19 infection.